TENAGRITY SOLUTIONS, LLC

Lobbying for 1DAY SOONER ACTION PROJECT · advocacy organization supporting medical research

Amended

The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Apr 21, 2025.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Income

$20,000.00

What the client paid this registrant for the period.

Client based in

Delaware

Official filing document

Lobbyists on this filing 1

JENNY CAROLINE DEBERRY

Previously held: Senior Legislative Assistant/ Legislative Assistant, Congressman John J. Duncan, Jr.; Senior Campaign Finance Analyst/ Campaign Finance Analyst, Federal Election Commission

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 4

Defense, Dept of (DOD)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 3

Health Issues

Pandemic and All-Hazards Preparedness and Response Act (PAHPA) and Prescription Drug User Fee Act (PDUFA) and House and Senate FY26 appropriations bills (and report language) to ensure: adequate resources for HHS and interagency / interdepartmental relationships for emerging pathogen and pandemic preparedness; prioritization of improved indoor air quality in military and other federal facilities to promote health (additional legislation on this topic: NDAA); FDA reforms including maximized use of AI. Support for Sen. Cassidy's anticipated HEP-C elimination legislation (including specifically clinical trial research). Communication with congressional offices re: enabling greater use of human challenge studies. Discussions with House and Senate offices about potential new legislation related to how the government encourages innovation in health care and other industries. Discussions with the HHS and DoD to support the FDA - DoD relationship to prioritize the development of safe and effective medical products that could save military personnel lives

Medical/Disease Research/Clinical Labs

Pandemic and All-Hazards Preparedness and Response Act (PAHPA) and Prescription Drug User Fee Act (PDUFA) and House and Senate FY26 appropriations bills (and report language) to ensure: adequate resources for HHS and interagency / interdepartmental relationships for emerging pathogen and pandemic preparedness; prioritization of improved indoor air quality in military and other federal facilities to promote health (additional legislation on this topic: NDAA); FDA reforms including maximized use of AI. Support for Sen. Cassidy's anticipated HEP-C elimination legislation. Support for Sen. Cassidy's anticipated HEP-C elimination legislation (including specifically clinical trial research). Communication with congressional offices re: enabling greater use of human challenge studies. Discussions with House and Senate offices about potential new legislation related to how the government encourages innovation in health care and other industries. Discussions with the HHS and DoD to support the FDA - DoD relationship to prioritize the development of safe and effective medical products that could save military personnel lives

Defense

Pandemic and All-Hazards Preparedness and Response Act (PAHPA) and Prescription Drug User Fee Act (PDUFA) and House and Senate FY26 appropriations bills (and report language) to ensure: adequate resources for HHS and interagency / interdepartmental relationships for emerging pathogen and pandemic preparedness; prioritization of improved indoor air quality in military and other federal facilities to promote health (additional legislation on this topic: NDAA); FDA reforms including maximized use of AI. Support for Sen. Cassidy's anticipated HEP-C elimination legislation. Discussions with House and Senate offices about potential new legislation related to how the government encourages innovation in health care and other industries. Discussions with the HHS and DoD to support the FDA - DoD relationship to prioritize the development of safe and effective medical products that could save military personnel lives

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.